



Pharmaceuticals Limited

**Registered & Corporate Office :**

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,  
Opp. SBI Executive Enclave, Banjara Hills,  
Hyderabad - 500 034, Telangana, INDIA.  
Tel : +91-40-2525 9999, Fax : +91-40-2525 9889  
CIN : L24239TG1987PLC008066  
Email: info@smspharma.com, www.smspharma.com

Date: 25<sup>th</sup> May, 2023

To,  
The Manager,  
Corporate Filings Department,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001

The Manager,  
Listing Compliance Department,  
National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051.

**Security Code: 532815**

**Symbol: SMSPHARMA**

Dear Sir/Madam,

**Sub: Investor Presentation**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing here herewith a copy of investor presentation of the Company for the fourth quarter and financial year ended 31<sup>st</sup> March, 2023.

This Investor Presentation may also be accessed on the website of the Company at [www.smspharma.com](http://www.smspharma.com)

Kindly take the same on record and disseminate on your website.

Thanking you  
Yours Faithfully

**For SMS Pharmaceuticals Limited**

**Thirumalesh Tumma**  
Company Secretary

# SMS Pharmaceuticals Limited

## Investor Presentation

May 2023





This presentation and the accompanying slides (the “Presentation”), which have been prepared by **SMS Pharmaceuticals Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

# Table of Contents

 <a href="#">Company Overview</a> .....	04-20
 <a href="#">Key Strategic Focus</a> .....	21-27
 <a href="#">Financial Highlights</a> .....	28-33
 <a href="#">Historical Performance at a Glance</a> .....	34-38



# Company Overview





# Company at a Glance

## Genesis

- A 30-years old research-driven company headquartered in Hyderabad.
- API focused company with 2 world class operating facilities in Hyderabad & Vizag, India.
- Backward-integrated with low dependency on imports for raw material

## Integrated model

- 80% of the intermediates are consumed by the API in-house business. Low import dependency.
- JV with Spanish pharma giant Chemo Iberica S.A. for R&D
- Vertically integrated through VKT Pharmaceuticals Pvt. Ltd. - An Associate company for semi-finished and finished formulations

## API Business

- ~96% of revenue is derived through API business
- 40+ products spread across 14 therapeutic segments.
- Top therapeutic segments - Anti-Diabetic, Anti-Ulcer, Anti-Migraine, ARV, Anti-Epileptic, Anti-Inflammatory & Anti-Erectile Dysfunction
- Global and Domestic leadership in key complex, specialized products like Famotidine, Rizatriptan Benzoate, Tadalafil, Sumatriptan Succinate, Itraconazole, Eletriptan HBr, Ibuprofen, Tenofavir, Ranolazine, Levetiracetam, Lamuvidine, Lamotrigine, Efavirenz & Sitagliptin.



## CRAMS Business

- Engaged in providing quality alternative manufacturing destination to multinationals for their contract research and manufacturing needs.
- Installed Capacity: 1951 KL
- Top Customers: Mylan, Laurus, Pharmathen & Lupin
- Other Details: Huge manufacturing facility to support various range of APIs


## Reach

- 800+ Customers
- 75+ Countries
- 40+ Products
- 80+ Regulatory Fillings
- 30+ Process Patents

## Capacity Overview

- Hyderabad Plant:
  - Installed Capacity: 120 KL
  - Products: Famotidine, Rizatriptan Benzoate, Tadalafil, Sumatriptan Succinate, Itraconazole, Eletriptan HBr
- Visakhapatnam Plant:
  - Installed Capacity: 3,000 KL
  - Products: Ibuprofen, Tenofavir, Ranolazine, Levetiracetam, Lamuvidine, Lamotrigine, Efavirenz & Sitagliptin.
  - One of the largest single-block, single-product plant in Asia
- Certifications : USFDA, EUGMP, KFDA, CDCSO & PMDA

# Transformation Over the Years



# Highly Competent Team...To Drive the Future Growth



**Mr. Ramesh Babu Potluri**  
Chairman & MD

- Post-graduate Technocrat.
- Started his career in the year 1984 with Cheminor Drugs Limited (Group of Dr. Reddy's Laboratory), Hyderabad.
- Played a key role in getting US FDA approval for Ibuprofen
- With his innovative skills and methodological approaches in R & D he developed cost effective Ibuprofen by using cyanide route.
- Acquired SMS Pharmaceuticals Limited in 1990 and became the Managing Director of the Company.



**Mr. P. Sarath Kumar**  
Director

- Founder partner of the Sarath & Associates.
- Chartered Accountant with about 26 years of standing in the Profession of Chartered Accountancy and Consulting.
- Bachelor of Law and Certified Fraud Examiner & Certified Forensic Accounting Professional.
- Advisor to C.I.D. of AP Police and Central Bureau of Investigation in investigation of major Economic Offence cases and is a Member of Multi Disciplinary Investigation team.



**Sri Sarvepalli Srinivas**  
Director

- Holds a B.Com. Degree from the University of Delhi.
- Accomplished Business leader with 3+ decades of proven leadership experience in leading Public / Private Sector enterprises with decisive and forward thinking with a strong vision and strategic capability.
- 32+ years of experience in leading Public / Private Sectors)-National Handloom Development Corporation Ltd (NHDC) – Managing Director -National Textile Corporation Ltd (NTC) – Chairman & Managing Director.



**Sri Sravan Kudravalli**  
Director

- Commerce Graduate from Osmania University and a Fellow member of the Institute of Chartered Accountants of India.
- Partner in a reputed Chartered Accountancy firm and has experience in the area of Auditing, Accountancy, Company Law matter, Income Tax and Finance.
- Involved in handling Internal and Statutory Audits of various Public and Private Companies and Systems designing for clients.




**Mr. Vamsi Krishna Potluri**  
Executive Director


- Bachelor's in Engineering in EEE from BITS Pilani Dubai Campus. And Masters in Engineering Management from Missouri University of Science & Technology- Rolla.
- Joined Ohm Labs – the biggest manufacturing hub of Ranbaxy in US in the supply chain group and had hands on experience in managing the supply chain.
- Eldest son of Mr. Ramesh Babu Potluri, Chairman and Managing Director, SMS Pharmaceuticals Ltd.



# State-of-the-art Manufacturing Facilities



Particulars	Hyderabad	Visakhapatnam
<b>Year of Establishment</b>	2000	2010
<b>Area (units in Sq. M)</b>	Plant Area: 19,685 Built Up: 5,127	Plant Area: 3,45,007 Built Up: 39,704
<b>Capacity</b>	120KL	3,000 KL
<b>Key Products</b>	Famotidine, Rizatriptan Benzoate, Tadalafil, Sumatriptan Succinate, Itraconazole, Eletriptan HBr etc.	Ibuprofen, Tenofavir, Ranolazine, Levetiracetam, Lamuvidine, Lamotrigine, Efavirenz, Sitagliptin etc.
<b>Regulatory Approvals</b>	USFDA, EUGMP, KFDA, CDSCO, PMDA	USFDA, KFDA, CDSCO, PMDA
<b>Key Features</b>	<ul style="list-style-type: none"> <li>5 times approved by USFDA.</li> <li>Facility aligned for manufacturing niche small volume molecules.</li> <li>One of the largest exporter of Triptans</li> </ul>	<ul style="list-style-type: none"> <li>3 times approved by USFDA.</li> <li>Flagship, Multipurpose API manufacturing facility.</li> <li>Facility aligned for manufacturing niche large-volume molecules.</li> <li>Huge CMO facility to cater highly reputed clients</li> <li>Dedicated Ibuprofen largest single-block, single product plant in Asia</li> </ul>



# Self-reliant Manufacturing Plants



- Pre-treatment plant capacity (MGF & Softner) 1750 Lts/ Hr.
  - DM Water generation by RO & EDI - 1000 Lts / Hr.
  - DM Water Storage capacity – 5000 Lts
- Power Generation by DG set 640 KV & 320 KV. Boilers 2Tons/Hr. & 3 Tons/Hr.
- Vacuum Pumps, Steam & Water jet ejectors & Nitrogen Plant 20 NM3/ Hr.

Particulars	No.
Total No. of Reactors	50
Minimum Size	50 L
Maximum Size	3,000 L
Total Capacity	57 KL
Glass Lined Reactors	17
SS Reactors	31
Hydro-generators	2
Distillation Still	1
Glass Flasks	5
SS Centrifuges	18
Rubber Lined Centrifuges	1
Dryers	16

# ...and a Wide Array of Manufacturing Capabilities

Equipment Name	MOC	Capacity (Min-Max)
Stainless steel Reactors	SS	50 L – 32 KL
Glass lined Reactors	MS-GL	63 L – 10 KL
Leaf Filters	SS	80 – 100 L
Nutsch Filters	SS	80 – 1500 L
Agitated Nutsche Filter Drier	SS	2500 – 15000 L
Sparkler Filter	SS	10-177 L
Centrifuges	SS	24" - 60"
Rotary Cone Vacuum Drier	SS & MS GL	200 L – 3000 L
Vacuum Tray Drier / Tray drier	SS	12 – 96 Trays
De-lumper	SS	1000 – 2000 Kg/Hr
Fluid Bed Drier	SS	300 – 500 Kg
Co-Mill	SS	500 – 750 Kg/Hr
Multi Mill	SS	50-300 Kg/Hr
Poly Gonal Blender	SS	150 L – 3 KL
Micronizer	SS	20 – 200 Kg/Hr
Micro Pulverizer	SS	50-250 Kg/Hr
Sifter	SS	100-500 Kg/Hr
Roller Compactor	SS	400 Kg/Hr

Note: SS – Stainless Steel , MS GL – Mild Steel Glass Lined





# ...Resulting into Long Lasting Relationships with Marquee Clients



# Certifications



✓ *Society Service*



✓ *Educational Infrastructure*



✓ *Empowering Differently Abled Children*





✓ **Sponsored & Constructed Z.P. High School at Poosapatriga Village, Andhra Pradesh**



✓ **Sponsored for Borewell drilling Chinthapalli Village, Andhra Pradesh**



✓ **Donation of Oxygen cylinders at Kopperla Village in aid of Covid 19 victims**





- ✓ **Sponsored & Constructed R.O water plant at Thammayapalem Viliage, Andhra Pradesh**



- ✓ **We also Donated INR 20 Lakh to the police force to support their selfless service during covid times.**

- ✓ **Extended financial support to Campus challenge**





## ✓ *Sponsored & Constructed: AP Balayogi Gurukulam, Kopperala, Vizianagaram, Andhra Pradesh*





✓ **Financial Sponsored to MPUP School, Ayyanapet, Vizianagaram, Andhra Pradesh**



# Awards/Accolades

## Indo US NCGC Award

- ❑ First Indian pharma company to receive **Indo-US GCNC award** for adopting green chemistry practices



## Pandit Jawaharlal Nehru Silver Rolling Trophy

- ❑ Awarded **Pandit Jawaharlal Nehru Silver Rolling Trophy** for the best productivity effort in Andhra Pradesh



## Bulk Drug Company of the Year

- ❑ **India Pharma Bulk Drug Export Company of the Year Award** from Government of India.





- ❑ Received the **Indian Pharma Bulk Drug Company of the Year Award**






# Key Strategies











## Leadership in Select High-Value, Complex APIs


 API portfolio comprises of specialized and profitable products in niche therapeutic areas. Reflects the strong ability to foray into other high-value, niche and complex products

 Currently developing multiple products every year across 14 therapeutic areas, which include High Value as well as High Volume Products


 SMS Pharma has demonstrated an ability in the past to foray into new complex, profitable products and currently enjoys leadership position in multiple API molecules.

 The company has presence in multiple margin-lucrative, non-commoditized therapeutic areas like ARV, Anti-Epileptic, Anti-Migraine, Anti-Anginal, etc.


 The company has an expertise in synthesis and R&D which can be leveraged to foray into complex API products and therapies

 The company enjoys global leadership position across 10+ products across therapies.

## Growing share of High Value Products



- ARV
- Anti-Epileptic
- Anti-Migraine
- Anti-Diabetic
- Anti-Ulcer
- Anti-Anginal
- Anti-Inflammatory
- Other



- ARV
- Anti-Epileptic
- Anti-Anginal
- Anti-Migraine
- Anti-inflammatory
- Anti-Diabetic
- Other



**With ~ Rs. 200 crores capex at Vishakhapatnam Facility in FY21, the company is fully geared up for the next level of growth.**

- The brownfield capex is aimed towards capacity augmentation of multiple products and therapies.
- The incremental capacity addition through the capex is 1,300 KL, predominantly aimed towards Ibuprofen capacity expansion.
- With this capex, **company is expected to be one of the largest Ibuprofen manufacturers globally.**
- The company is also leveraging long-standing relationships, domain expertise and strong R&D **knowledge to foray into new therapies, products and geographies**
- **Majority of the capex is funded through internal accruals and minimal debt, thus maintaining the robust Balance Sheet position.**
- **Higher margins and profitability ratios expected through operating leverage and incremental revenue.**

# Unique Value Proposition

## Global Presence

~83% Exports Revenue (including deemed exports) in 75+ countries across 5 continents – **Lower dependency on single country/region**



## Strong Domain Expertise

Promoters and Senior Management with a strong business pedigree and domain expertise in APIs and Intermediates – **Alignment of interest of all internal stakeholders**



## Cost Leadership

From procurement to production till sales have a strong foundation and sound setup. Backward integration ensures cost-efficient manufacturing – **Higher Profitability**



## Long-standing Relationships

Long standing relationships with suppliers and customers - **Cost-efficient, consistent, sustainable raw material supply and revenue**




## Economies of Scale

Leadership position in key products, coupled with backward integration provides economies of scale – **Lower Competitive Intensity & Higher Margins**



Well-diversified across Geographies, Markets, Therapies, Products and Customers = Risk Reduction and Multiple Growth Avenues




## Geography

- Domestic - Export mix at **17%:83%** for FY23
- Presence across **75+ countries**
- None of the region contributes **more than 2/3rd** of the revenue, with **Europe** contributing the highest at **~47%** of total sales



## Markets

- Regulated Markets contributed **~76%** of sales in FY23, with **Spain** being the highest at **~34%**
- Semi- Regulated Markets contributed **~7%** of sales in FY23, with **Africa** being the highest at **~3%**
- Domestic Markets contributed **~17%** of sales in FY23, with **Lupin** being the highest at **~10%**.



## API Therapies

- Top 5 therapies contributed **~84%** of sales in FY23
- Anti Diabetic products contributed highest at **38%** to sales in FY23
- Top 10 products contributed to **84%** to sales in FY23
- Leaders in Domestic market in most of top 10 products



## Customers

- Domestic: Largest client contributes **~10%** of domestic sales whereas top 10 clients contribute **~66%** in FY23.
- Exports: Largest client contributes **~39%** of exports sales whereas top 10 clients contribute **~66%** in FY23.





## Backward Integration

- Over the years, SMS Pharma has strategically invested in backward integration to be self-reliant and reduce supply chain risk.
  - 80% of the intermediates are consumed by the API in-house business.
  - Low dependency on China for raw material sourcing (~10% of the raw material sourced from China)



## Verticle Integration

- Vertically integrated through VKT Pharmaceuticals Pvt. Ltd. - An Associate company
  - VKT Pharma Private Limited is engaged in manufacture of formulations & semi-finished formulations viz. pellets.
  - Company holds 36.55% as on 31<sup>st</sup> March 2023 in VKT Pharma and balance is held by promoters which give the entire control in the manufacturing cycle.
  - VKT Pharma gives an edge by saving costs & eliminating imports with respect to formulations.
  - VKT has 6 approved ANDA's out of which 4 received in January 2022.


# Financial Highlights



# Consolidated Revenue Break-up – Quarterly


Segment-wise

Q4FY22




■ API ■ Intermediates & Others

Q3FY23



■ API ■ Intermediates & Others


Q4FY23



■ API ■ Intermediates & Others


Geography-wise

Q4FY22




■ Domestic ■ Exports

Q3FY23



■ Domestic ■ Exports

Q4FY23




■ Domestic ■ Exports



# Consolidated Revenue Break-up – YTD


Segment-wise

FY22



■ API   ■ Intermediates & Others


FY23



■ API   ■ Intermediates & Others


Geography-wise

FY22



■ Domestic   ■ Exports


FY23




■ Domestic   ■ Exports

# API Therapy-wise Revenue Break-up – Quarterly


**Q4FY22**



**Q3FY23**



**Q4FY23**




- ARV
- Anti-Ulcer
- Anti-Erectile Dysfunction
- Anti-Migraine
- Anti-Epileptic
- Anti-Diabetic
- Others

- ARV
- Anti-Ulcer
- Anti-Erectile dysfunction
- Anti-Migraine
- Anti-Epileptic
- Anti-Diabetic
- Others

- ARV
- Anti-Ulcer
- Anti-Erectile dysfunction
- Anti-Migraine
- Anti-Epileptic
- Anti-Diabetic
- Others


# API Therapy-wise Revenue Break-up – YTD

FY22



- ARV
- Anti-Ulcer
- Anti-Erectile Dysfunction
- Anti-Migraine
- Anti-Epileptic
- Anti-Diabetic
- Others

FY23



- ARV
- Anti-Ulcer
- Anti-Erectile dysfunction
- Anti-Migraine
- Anti-Epileptic
- Anti-Diabetic
- Others



# Consolidated Profit & Loss Statement

Particulars (Rs. Crores)	Q4 FY23	Q3FY23	QoQ%	Q4 FY22	YoY%	FY23	FY22	YoY%
<b>Net Revenue from Operations</b>	<b>149.4</b>	<b>148.8</b>	<b>0%</b>	<b>60.9</b>	<b>145%</b>	<b>522.1</b>	<b>519.9</b>	<b>0%</b>
Other Income	1.3	2.2		0.4		4.9	5.2	
Total Revenue	150.7	151.0		61.4		526.9	525.1	
COGS	86.5	97.4		33.6		335.8	275.5	
<b>Gross Profit</b>	<b>64.2</b>	<b>53.6</b>	<b>20%</b>	<b>27.8</b>	<b>131%</b>	<b>191.1</b>	<b>249.6</b>	<b>-23%</b>
<b>Gross Margin (%)</b>	<b>43.0%</b>	<b>36.0%</b>	<b>691Bps</b>	<b>45.6%</b>	<b>-260Bps</b>	<b>36.6</b>	<b>48.0%</b>	<b>-1140Bps</b>
Employee Expenses	15.8	13.6		13.8		55.0	51.0	
Other Expenses	23.9	19.3		18.0		76.7	79.1	
<b>EBITDA</b>	<b>24.5</b>	<b>20.7</b>	<b>18%</b>	<b>-4.0</b>	<b>N.A.</b>	<b>59.4</b>	<b>119.5</b>	<b>-50%</b>
<b>EBITDA Margin (%)</b>	<b>16.4%</b>	<b>13.9%</b>	<b>246Bps</b>	<b>-6.6%</b>	<b>N.A.</b>	<b>11.4</b>	<b>23.0%</b>	<b>-1161bps</b>
Finance Costs	5.9	5.9		4.3		21.9	18.9	
Depreciation	8.0	8.1		8.0		32.1	32.2	
<b>PBT</b>	<b>10.6</b>	<b>6.7</b>	<b>59%</b>	<b>-16.3</b>	<b>N.A.</b>	<b>5.3</b>	<b>68.5</b>	<b>-92%</b>
Taxes	2.6	1.4		-25.2		1.5	0.6	
<b>Reported PAT</b>	<b>8.1</b>	<b>5.3</b>	<b>53%</b>	<b>8.9*</b>	<b>-9%</b>	<b>3.9</b>	<b>67.9*</b>	<b>-94%</b>
Add: Share of Associate Profit / (Loss)	-1.9	-1.5		-2.7		-10.9	-5.7	
<b>PAT After MI &amp; Assoc.</b>	<b>6.2</b>	<b>3.8</b>	<b>65%</b>	<b>6.2</b>	<b>1%</b>	<b>-7.1</b>	<b>62.2</b>	<b>N.A.</b>
<b>PAT Margin</b>	<b>5.4%</b>	<b>3.5%</b>	<b>185Bps</b>	<b>14.6%</b>	<b>-921Bps</b>	<b>0.7%</b>	<b>13.1%</b>	<b>N.A.</b>
<b>EPS</b>	<b>0.73</b>	<b>0.44</b>	<b>66%</b>	<b>0.73</b>	<b>0%</b>	<b>-0.83</b>	<b>7.35</b>	<b>N.A.</b>


\*Includes reversal of deferred tax liability amounting to Rs. 22.15 crores in Q4F22 and Rs. 14.30 crores in FY22.

# Historical Performance at a Glance




# Historical Financial Performance


### Revenue (Rs. Crores)




### EBITDA (Rs. Crores)




### PAT (Rs. Crores)




### EBITDA Margin (%)



### Net Worth (In Crores)



### Leverage (X)





# Consolidated Profit & Loss Statement

Particulars (Rs. crores)	FY23	FY22	FY21	FY20	FY19	FY18
<b>Net Revenue from Operations</b>	<b>522.1</b>	<b>519.9</b>	<b>563.2</b>	<b>411.9</b>	<b>464.9</b>	<b>464.9</b>
Other Income	4.9	5.2	3.5	5.1	3.4	2.4
COGS	335.8	275.5	340.0	246.4	292.7	289.9
<b>Gross Profit</b>	<b>191.1</b>	<b>249.6</b>	<b>226.6</b>	<b>170.60</b>	<b>175.6</b>	<b>177.4</b>
<b>Gross Margin (%)</b>	<b>36.6%</b>	<b>48.0%</b>	<b>40.2%</b>	<b>41.4%</b>	<b>37.8%</b>	<b>38.2%</b>
Employee Expenses	55.0	51.0	41.2	39.4	34.8	34.5
Other Expenses	76.7	79.1	60.9	46.3	46.5	48.8
<b>EBITDA</b>	<b>59.4</b>	<b>119.5</b>	<b>124.6</b>	<b>85.0</b>	<b>93.5</b>	<b>95.72</b>
<b>EBITDA Margin (%)</b>	<b>11.4%</b>	<b>23.0%</b>	<b>22.1%</b>	<b>20.6%</b>	<b>20.1%</b>	<b>20.6%</b>
Finance Costs	21.9	18.9	11.2	12.2	11.9	15.5
Depreciation	32.1	32.2	22.3	22.1	19.3	19.9
<b>PBT before exceptional item</b>	<b>5.3</b>	<b>68.5</b>	<b>91.1</b>	<b>50.7</b>	<b>62.4</b>	<b>60.3</b>
Exceptional Expense/(Gain)	0.0	0.0	0.0	0.0	0.0	0.0
Share in Profit/(loss) in JV and Associates	-10.9	-5.7	1.6	-1.1	-1.4	-8.7
<b>PBT</b>	<b>-5.6</b>	<b>62.8</b>	<b>92.7</b>	<b>49.6</b>	<b>61.0</b>	<b>51.6</b>
Taxes	1.5	0.6	30.2	18.1	20.9	19.9
<b>Reported PAT</b>	<b>-7.1</b>	<b>62.2</b>	<b>62.5</b>	<b>31.6</b>	<b>40.1</b>	<b>31.7</b>
<b>Cash PAT</b>	<b>25.1</b>	<b>94.4</b>	<b>84.8</b>	<b>53.6</b>	<b>59.4</b>	<b>51.6</b>
<b>PAT Margin (%)</b>	<b>0.7%</b>	<b>13.1%</b>	<b>11.1%</b>	<b>7.7%</b>	<b>8.6%</b>	<b>6.8%</b>
Earnings Per Share (EPS)	-0.83	7.35	7.39	3.73	4.73	3.75

# Consolidated Balance Sheet

Equities & Liabilities (Rs. crores)	FY23	FY22	FY21	FY20	FY19	FY18
<b>Equity</b>						
Equity Share capital	8.5	8.5	8.5	8.5	8.5	8.5
Other Equity	452.0	461.8	402.0	339.8	313.5	276.0
Non Controlling Interest	0.0	0.0	0.0	0.0	0.0	0.0
<b>Total Equity</b>	<b>460.6</b>	<b>470.3</b>	<b>410.5</b>	<b>348.2</b>	<b>321.9</b>	<b>284.5</b>
Financial liabilities						
(i) Borrowings	121.1	149.5	147.8	68.2	62.2	71.4
(ii) Other Financial liabilities	0.6	2.1	4.1	4.8	0.0	0.0
Other non current Liability	0.0	0.0	0.0	0.0	0.0	0.0
Deferred tax liabilities (Net)	41.0	39.6	53.9	39.7	30.6	23.0
Provisions	1.4	1.6	1.8	1.7	1.5	2.2
<b>Total Non Current Liabilities</b>	<b>164.2</b>	<b>192.8</b>	<b>207.6</b>	<b>114.5</b>	<b>94.3</b>	<b>96.6</b>
Financial liabilities						
(i) Borrowings	131.4	110.6	70.9	61.2	70.8	58.4
(ii) Lease Liabilities	0.9	1.0	0.0	0.0	0.0	0.0
(iii) Trade Payables	113.2	72.9	65.4	44.5	47.7	38.7
(iii) Other financial liabilities	5.5	6.8	48.80	28.4	13.0	17.5
Provisions	1.0	1.0	0.8	0.7	0.7	0.7
Other current liabilities	2.9	4.2	8.2	10.4	10.4	5.9
Current tax liabilities (Net)	0.0	0.0	0.0	0.0	0.0	0.0
<b>Total Current Liabilities</b>	<b>254.9</b>	<b>196.5</b>	<b>194.1</b>	<b>145.2</b>	<b>142.5</b>	<b>121.5</b>
<b>Total Equity and Liabilities</b>	<b>879.6</b>	<b>859.6</b>	<b>812.20</b>	<b>607.9</b>	<b>558.8</b>	<b>502.5</b>

Assets (Rs. crores)	FY23	FY22	FY21	FY20	FY19	FY18
<b>Non Current assets</b>						
Property, Plant and Equipment	409.5	434.1	452.3	275.2	280.1	278.9
Capital work in progress	33.2	11.0	6.7	42.1	18.3	8.2
Intangible assets	1.5	1.4	1.6	0.8	1.1	0.4
Right to use assets	1.1	2.6	3.6	4.5	0.0	0.0
Financial Assets	0.0	0.0	0.0	0.0	0.0	0.0
(i) Investments	10.5	21.5	27.3	25.8	27.0	28.4
(ii) Other Financial Assets	7.6	7.6	5.8	5.6	5.6	4.4
Deferred Tax Assets (net)	0.0	0.0	0.0	0.0	0.0	0.0
Other non-current assets	5.6	4.3	5.6	35.1	19.1	13.8
<b>Total Non Current Assets</b>	<b>469.0</b>	<b>482.5</b>	<b>502.9</b>	<b>389.1</b>	<b>351.2</b>	<b>334.0</b>
Current Assets						
Inventories	223.5	251.1	137.8	129.2	136.4	107.5
Financial Assets	0.0	0.0	0.0	0.0	0.0	0.0
Investments	0.0	0.0	0.0	0.0	0.0	0.0
(i) Trade receivables	148.3	48.5	105.7	48.8	26.0	24.1
(ii) Cash and Bank Balances	7.4	46.5	40.4	9.5	14.8	12.6
(iii) Bank Balances & Financial Assets	6.6	2.9	0.4	0.4	0.3	0.6
Current Tax Assets(Net)	5.8	4.5	3.0	3.1	0.4	0.0
Other current assets	19.0	23.5	22.0	27.8	29.6	23.6
<b>Total Current Assets</b>	<b>410.6</b>	<b>377.1</b>	<b>309.3</b>	<b>218.8</b>	<b>207.6</b>	<b>168.5</b>
Non current Asset held for sale		0.0	0.0	0	0.0	0.0
<b>Total Assets</b>	<b>879.6</b>	<b>859.6</b>	<b>812.2</b>	<b>607.9</b>	<b>558.8</b>	<b>502.5</b>

# Consolidated Cashflow Statement

Particulars (Rs. crores)	FY23	FY22	FY21	FY20	FY19	FY18
<b>Net Profit before Tax and Extraordinary items</b>	<b>5.4</b>	<b>68.5</b>	<b>91.1</b>	<b>50.8</b>	<b>62.4</b>	<b>60.3</b>
Adjustments for: Non Cash Items / Other Investment or Financial Items	53.0	49.9	27.8	28.7	26.8	31.1
<b>Operating profit before working capital changes</b>	<b>58.3</b>	<b>118.4</b>	<b>118.9</b>	<b>79.4</b>	<b>89.2</b>	<b>91.4</b>
Changes in working capital	<b>-31.3</b>	-58.4	-12.4	-27.6	-26.0	-48.5
<b>Cash generated from Operations</b>	<b>27.1</b>	<b>60.0</b>	<b>106.5</b>	<b>51.8</b>	<b>63.1</b>	<b>43.0</b>
Direct taxes paid (net of refund)	<b>-4.6</b>	-14.9	16.0	12.1	13.4	11.1
<b>Net Cash from Operating Activities</b>	<b>22.5</b>	<b>45.1</b>	<b>90.5</b>	<b>39.7</b>	<b>49.8</b>	<b>31.8</b>
<b>Net Cash from Investing Activities</b>	<b>-29.7</b>	<b>-27.2</b>	<b>-151.6</b>	<b>-42.6</b>	<b>-34.7</b>	<b>-16.6</b>
<b>Net Cash from Financing Activities</b>	<b>-32.0</b>	<b>-11.8</b>	<b>92.0</b>	<b>-2.4</b>	<b>-12.9</b>	<b>-14.9</b>
Net Decrease in Cash and Cash equivalents	-39.2	6.2	30.9	-5.3	2.2	0.3
Add: Cash & Cash equivalents at the beginning of the period	46.6	40.4	9.5	14.8	12.6	12.3
<b>Cash &amp; Cash equivalents at the end of the period</b>	<b>7.4</b>	<b>46.6</b>	<b>40.4</b>	<b>9.5</b>	<b>14.8</b>	<b>12.6</b>

**For further information, please contact**

**Company:**



CIN: L24239TG1987PLC008066

Mr. Thirumalesh Tumma

Email: [complianceofficer@smspharma.com](mailto:complianceofficer@smspharma.com)

Contact no.: +91 9100123244

[www.smspharma.com](http://www.smspharma.com)

**Investor Relations Advisor:**

**SGA** Strategic Growth Advisors

CIN: U74140MH2010PTC204285

Mr. Jigar Kavaiya / Mr. Parin Narichania

E: [jigar.kavaiya@sgapl.net](mailto:jigar.kavaiya@sgapl.net) / [parin.n@sgapl.net](mailto:parin.n@sgapl.net)

T: +91 9920602034 / +91 9930025733

[www.sgapl.net](http://www.sgapl.net)